Julian Baker portfolio · Q4 2025
Baker Bros. Advisors LP · CIK 0001263508 ·13F filings on SEC EDGAR
In Q4 2025, Baker Bros. Advisors LP reported 86 positions worth $17.1B. Its largest holding was INCY at 17.8% of the portfolio, and the top 10 made up 74%. This is the earliest quarter available here, so changes are not shown.
Portfolio map
Each box is a position sized by its value. There is no previous quarter here to compare changes. The smallest 46 positions are grouped as one box.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
INCY INCYTE CORP | 17.78% | $89.91* | $121.35 | +35.0% | $3.7B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 15.65% | $136.93* | $365.94 | +167.2% | $3.2B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 7.30% | $195.25 | $503.96 | +158.1% | $1.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 6.72% | $76.22* | $114.14 | +49.7% | $752.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACAD ACADIA PHARMACEUTICALS INC | 6.71% | $25.45* | $20.15 | -20.8% | $864.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 4.62% | $24.80 | $79.52 | +220.6% | $629.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 4.41% | $30.16 | $205.26 | +580.6% | $1.9B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYMR KYMERA THERAPEUTICS INC | 3.94% | $37.07 | $111.79 | +201.6% | $967.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SMMT SUMMIT THERAPEUTICS INC | 3.73% | $12.42 | $16.91 | +36.1% | $615.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 3.51% | $24.92 | $95.22 | +282.1% | $533.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KOD KODIAK SCIENCES INC | 3.26% | $33.47 | $94.80 | +183.2% | $1.9B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 1.94% | $145.19 | $291.23 | +100.6% | $328.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALKS ALKERMES PLC | 1.64% | $26.97 | $40.52 | +50.2% | $405.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 1.05% | $32.64 | $140.12 | +329.3% | $292.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 0.96% | $15.77 | $40.60 | +157.4% | $267M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.85% | $33.82 | $65.45 | +93.5% | $142.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.83% | $74.78 | $44.65 | -40.3% | $80M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.81% | $21.09 | $33.78 | +60.2% | $184.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 0.74% | $8.87 | $8.78 | -1.0% | $106.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.73% | $23.04 | $38.42 | +66.8% | $139M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 0.71% | $13.76 | $36.57 | +165.7% | $203.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 0.69% | $84.90 | $99.02 | +16.6% | $86.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.68% | $18.70 | $74.61 | +298.9% | $210.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.63% | $13.45 | $13.24 | -1.5% | $146.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STOK STOKE THERAPEUTICS INC | 0.62% | $11.09 | $26.00 | +134.4% | $86.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GPCR STRUCTURE THERAPEUTICS INC | 0.58% | $20.84 | $31.27 | +50.0% | $44.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABCL ABCELLERA BIOLOGICS INC | 0.55% | $18.61 | $14.59 | -21.6% | $401.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.52% | $24.49 | $23.71 | -3.2% | $110.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMCR IMMUNOCORE HOLDINGS PLC-ADR | 0.47% | $38.09 | $30.29 | -20.5% | $70.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.45% | $20.78 | $3.68 | -82.3% | $40.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 0.45% | $43.53 | $37.42 | -14.0% | $61.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.40% | $6.13 | $11.93 | +94.7% | $51.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.39% | — | — | — | $66.6M | |
RARE ULTRAGENYX PHARMACEUTICAL IN | 0.37% | $55.07 | $15.03 | -72.7% | $41.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 0.36% | $23.61 | $20.67 | -12.4% | $77.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.36% | $15.96 | $20.59 | +29.0% | $40.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRDA ENTRADA THERAPEUTICS INC | 0.31% | $16.68 | $6.35 | -61.9% | $32.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.27% | $23.18 | $33.60 | +44.9% | $52M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TERN TERNS PHARMACEUTICALS INC | 0.22% | $40.40 | $52.72 | +30.5% | $50.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.21% | $107.38 | $98.30 | -8.5% | $36.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 0.19% | $15.64 | $89.03 | +469.3% | $89M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNTH DIANTHUS THERAPEUTICS INC | 0.19% | $18.63 | $88.05 | +372.6% | $69.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.17% | $30.14 | $3.91 | -87.0% | $39.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.16% | $3.09 | $11.76 | +280.6% | $17.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 0.16% | $55.35 | $65.46 | +18.3% | $22.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.15% | $15.43 | $14.05 | -8.9% | $23.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.13% | $2.64 | $4.87 | +84.5% | $19.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.13% | $7.80 | $8.33 | +6.8% | $23.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTYX VENTYX BIOSCIENCES INC | 0.12% | $6.45 | $9.03 | +40.0% | $21.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARGX ARGENX SE - ADR | 0.12% | $79.01 | $958.91 | +1,113.7% | $24.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DSGN DESIGN THERAPEUTICS INC | 0.12% | $9.21 | $12.57 | +36.4% | $28.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CERS CERUS CORP | 0.12% | $4.94* | $2.38 | -51.8% | $23.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.12% | $12.31 | $27.82 | +126.0% | $27.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.11% | $20.51 | $23.29 | +13.5% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.11% | $2.44 | $2.72 | +11.7% | $11.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 0.11% | $22.62 | $32.41 | +43.3% | $21.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.10% | $18.16 | $24.95 | +37.4% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 0.10% | $25.01 | $39.72 | +58.8% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.10% | $21.68 | $37.19 | +71.5% | $13.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.10% | $10.46 | $5.26 | -49.7% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.10% | $11.77 | $13.42 | +14.0% | $19.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SERA SERA PROGNOSTICS INC-A | 0.09% | $5.59 | $2.09 | -62.6% | $11.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.09% | $19.56 | $16.11 | -17.6% | $13.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALMS ALUMIS INC | 0.09% | $13.30 | $7.39 | -44.4% | $11.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 0.08% | $76.30 | $123.50 | +61.9% | $17.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.06% | $24.95 | $31.72 | +27.1% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.06% | $13.52 | $18.05 | +33.5% | $20.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABSI ABSCI CORP | 0.04% | $3.49 | $10.77 | +208.6% | $23M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCUS ARCUS BIOSCIENCES INC | 0.04% | $23.83 | $25.83 | +8.4% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.04% | $17.56 | $10.19 | -42.0% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTVT VTV THERAPEUTICS INC- CL A | 0.03% | $23.47 | $30.84 | +31.4% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Y95308105 WAVE LIFE SCIENCES LTD | 0.03% | $8.20 | $5.81 | -29.1% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGMT SAGIMET BIOSCIENCES INC-A | 0.03% | $7.31 | $9.88 | +35.1% | $9.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.03% | $7.12 | $3.05 | -57.2% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.03% | $15.79 | $38.38 | +143.1% | $7.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.02% | $16.33 | $45.84 | +180.8% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.02% | $7.50 | $14.31 | +90.8% | $6.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VIR VIR BIOTECHNOLOGY INC | 0.02% | $7.34 | $11.18 | +52.3% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TCRX TSCAN THERAPEUTICS INC | 0.02% | $5.80 | $0.31 | -94.6% | $875.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SANA SANA BIOTECHNOLOGY INC | 0.01% | $4.35 | $2.92 | -32.9% | $905.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
83086J200 Skye Bioscience, Inc. | 0.01% | $5.31 | $0.69 | -86.9% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
483119202 KALA BIO INC | 0.01% | — | $0.17 | — | $312.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALGS ALIGOS THERAPEUTICS INC | 0.00% | $8.66 | $5.63 | -35.0% | $467.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 0.00% | $13.85 | $21.87 | +57.9% | $232K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRV ACRIVON THERAPEUTICS INC | 0.00% | $7.15 | $2.05 | -71.3% | $46.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $13.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
SEC filings for Q4 2025
- 13F-HR 0001104659-26-016374 · accepted Feb 17, 2026, 21:04 UTC